Update of pathophysiology and management of diabetic kidney disease
Diabetic kidney disease (DKD) is a major cause of morbidity and mortality in patients with diabetes mellitus and the leading cause of end-stage renal disease in the world. The most characteristic marker of DKD is albuminuria, which is associated with renal disease progression and cardiovascular even...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-08-01
|
| Series: | Journal of the Formosan Medical Association |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664617308033 |
| _version_ | 1818202127306063872 |
|---|---|
| author | Yi-Chih Lin Yu-Hsing Chang Shao-Yu Yang Kwan-Dun Wu Tzong-Shinn Chu |
| author_facet | Yi-Chih Lin Yu-Hsing Chang Shao-Yu Yang Kwan-Dun Wu Tzong-Shinn Chu |
| author_sort | Yi-Chih Lin |
| collection | DOAJ |
| description | Diabetic kidney disease (DKD) is a major cause of morbidity and mortality in patients with diabetes mellitus and the leading cause of end-stage renal disease in the world. The most characteristic marker of DKD is albuminuria, which is associated with renal disease progression and cardiovascular events. Renal hemodynamics changes, oxidative stress, inflammation, hypoxia and overactive renin-angiotensin-aldosterone system (RAAS) are involved in the pathogenesis of DKD, and renal fibrosis plays the key role. Intensified multifactorial interventions, including RAAS blockades, blood pressure and glucose control, and quitting smoking, help to prevent DKD development and progression. In recent years, novel agents are applied for preventing DKD development and progression, including new types of glucose-lowering agents, pentoxifylline, vitamin D analog paricalcitol, pyridoxamine, ruboxistaurin, soludexide, Janus kinase inhibitors and nonsteroidal minerocorticoid receptor antagonists. In this review, recent large studies about DKD are also summarized. Keywords: Diabetic kidney disease (DKD), Diabetic nephropathy (DN), Diabetes mellitus, Albuminuria |
| first_indexed | 2024-12-12T03:04:30Z |
| format | Article |
| id | doaj.art-180bd57797154209af40f879c4b509ad |
| institution | Directory Open Access Journal |
| issn | 0929-6646 |
| language | English |
| last_indexed | 2024-12-12T03:04:30Z |
| publishDate | 2018-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the Formosan Medical Association |
| spelling | doaj.art-180bd57797154209af40f879c4b509ad2022-12-22T00:40:32ZengElsevierJournal of the Formosan Medical Association0929-66462018-08-011178662675Update of pathophysiology and management of diabetic kidney diseaseYi-Chih Lin0Yu-Hsing Chang1Shao-Yu Yang2Kwan-Dun Wu3Tzong-Shinn Chu4Department of Medicine, National Taiwan University Hospital Jinshan Branch, New Taipei City, TaiwanDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, TaiwanDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Corresponding author. Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. Fax: +886 2 23934176.Department of Internal Medicine, National Taiwan University Hospital, Taipei, TaiwanDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, TaiwanDiabetic kidney disease (DKD) is a major cause of morbidity and mortality in patients with diabetes mellitus and the leading cause of end-stage renal disease in the world. The most characteristic marker of DKD is albuminuria, which is associated with renal disease progression and cardiovascular events. Renal hemodynamics changes, oxidative stress, inflammation, hypoxia and overactive renin-angiotensin-aldosterone system (RAAS) are involved in the pathogenesis of DKD, and renal fibrosis plays the key role. Intensified multifactorial interventions, including RAAS blockades, blood pressure and glucose control, and quitting smoking, help to prevent DKD development and progression. In recent years, novel agents are applied for preventing DKD development and progression, including new types of glucose-lowering agents, pentoxifylline, vitamin D analog paricalcitol, pyridoxamine, ruboxistaurin, soludexide, Janus kinase inhibitors and nonsteroidal minerocorticoid receptor antagonists. In this review, recent large studies about DKD are also summarized. Keywords: Diabetic kidney disease (DKD), Diabetic nephropathy (DN), Diabetes mellitus, Albuminuriahttp://www.sciencedirect.com/science/article/pii/S0929664617308033 |
| spellingShingle | Yi-Chih Lin Yu-Hsing Chang Shao-Yu Yang Kwan-Dun Wu Tzong-Shinn Chu Update of pathophysiology and management of diabetic kidney disease Journal of the Formosan Medical Association |
| title | Update of pathophysiology and management of diabetic kidney disease |
| title_full | Update of pathophysiology and management of diabetic kidney disease |
| title_fullStr | Update of pathophysiology and management of diabetic kidney disease |
| title_full_unstemmed | Update of pathophysiology and management of diabetic kidney disease |
| title_short | Update of pathophysiology and management of diabetic kidney disease |
| title_sort | update of pathophysiology and management of diabetic kidney disease |
| url | http://www.sciencedirect.com/science/article/pii/S0929664617308033 |
| work_keys_str_mv | AT yichihlin updateofpathophysiologyandmanagementofdiabetickidneydisease AT yuhsingchang updateofpathophysiologyandmanagementofdiabetickidneydisease AT shaoyuyang updateofpathophysiologyandmanagementofdiabetickidneydisease AT kwandunwu updateofpathophysiologyandmanagementofdiabetickidneydisease AT tzongshinnchu updateofpathophysiologyandmanagementofdiabetickidneydisease |